Is doxycycline post-exposure prophylaxis being utilised in Germany? Insights from an online survey among German men who have sex with men.
Doxycycline
Human immunodeficiency virus (HIV)
Post-exposure-prophylaxis (PEP)
Pre-exposure-prophylaxis (PrEP)
Sexually transmitted disease (STD)
Sexually transmitted infection (STI)
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
23 Jul 2024
23 Jul 2024
Historique:
received:
05
03
2024
accepted:
08
06
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
aheadofprint
Résumé
Doxycycline post-exposure prophylaxis (Doxy-PEP) reduces the likelihood of Chlamydia and early syphilis by approximately two-thirds. Currently, data on the frequency of Doxy-PEP use in men who have sex with men (MSM) are limited. This study aimed to assess knowledge, attitude towards, and frequency of Doxy-PEP use among MSM in Germany. We conducted a national online survey in Germany from summer to fall 2023, recruiting MSM and transgender women. Participants were invited to complete the online survey through social media, online dating platforms, and print media advertisements with active recruitment and poster advertising in private practices, tertiary outpatient clinics, and MSM community events in Germany. In total, 438 participants completed the survey and were included in the analysis, and 285 (65.1%) were living with the human immunodeficiency virus (HIV) or taking HIV-pre-exposure prophylaxis (PrEP). Overall, 170 participants (38.8%) had heard of Doxy-PEP, and 275 (62.8%) would consider taking it, but only 32 (7.3%) reported having ever taken Doxy-PEP. The most common reason for a negative attitude towards Doxy-PEP were apprehension about insufficient detailed information, and concerns about antibiotic resistance. Doxy-PEP users were more likely to be on HIV-PrEP, had a higher self-reported risk of bacterial sexually transmitted infections (STIs), and often had a history of bacterial STIs. The study demonstrated high awareness and strong interest in Doxy-PEP among MSM in Germany, most of whom were living with HIV or taking HIV-PrEP; however, the actual usage of Doxy-PEP remains low in the summer and fall of 2023.
Identifiants
pubmed: 39042326
doi: 10.1007/s15010-024-02321-x
pii: 10.1007/s15010-024-02321-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
World Health Organization. Sexually transmitted infections (STIs). 2021. https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis ). Accessed 27. Apr 2023.
Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2021. 2023. https://www.cdc.gov/std/statistics/2021/default.htm . Accessed 27. Apr 2023.
Centers for Disease Control and Prevention. CDC Response to Doxy-PEP data presented at 2022 International AIDS Conference. 2022. https://www.cdc.gov/nchhstp/newsroom/2022/Doxy-PEP-clinical-data-presented-at-2022-AIDS-Conference.html . Accessed 24. Nov 2023.
Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl Med. 2023;388:1296–306. https://doi.org/10.1056/NEJMoa2211934 .
doi: 10.1056/NEJMoa2211934
Molina J-M, Charreau I, Chidiac C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18:308–17. https://doi.org/10.1016/S1473-3099(17)30725-9 .
doi: 10.1016/S1473-3099(17)30725-9
pubmed: 29229440
Robert Koch Institut. Gonokokken-Resistenzsurveillance (Go-Surv-AMR). 2023. https://www.rki.de/DE/Content/InfAZ/G/Gonorrhoe/GORENET/GORENET_inhalt.html . Accessed 06. Apr 2023.
Stewart J, Oware K, Donnell D, et al. Doxycycline Prophylaxis to prevent sexually transmitted infections in women. N Engl Med. 2023;389:2331–40. https://doi.org/10.1016/S1473-3099(17)30725-9 .
doi: 10.1016/S1473-3099(17)30725-9
Science Media Center Germany gGmbH. Pille danach für sexuell übertragbare Krankheiten. 2023. https://www.sciencemediacenter.de/alle-angebote/research-in-context/details/news/pille-danach-fuer-sexuell-uebertragbare-krankheiten/ . Accessed 27. Apr 2023.
Spinelli MA, Scott HM, Vittinghoff E, et al. High interest in doxycycline for sexually transmitted infection postexposure Prophylaxis in a Multicity Survey of men who have sex with men using a social networking application. Sex Transm Dis. 2019;46:e32–4. https://doi.org/10.1097/OLQ.0000000000000942 .
doi: 10.1097/OLQ.0000000000000942
pubmed: 30870327
pmcid: 6425754
Carveth-Johnson T, Stingone C, Nwokolo N, et al. Doxycycline use in MSM taking PrEP. Lancet HIV. 2018;5:e482. https://doi.org/10.1016/S2352-3018(18)30210-8 .
doi: 10.1016/S2352-3018(18)30210-8
pubmed: 30215346
Fusca L, Hull M, Ross P, et al. High interest in Syphilis Pre-exposure and Post-exposure Prophylaxis among Gay, bisexual and other men who have sex with men in Vancouver and Toronto. Sex Transm Dis. 2020;47:224–31. https://doi.org/10.1097/OLQ.0000000000001130 .
doi: 10.1097/OLQ.0000000000001130
pubmed: 31977974
pmcid: 7077973
Park JJ, Stafylis C, Pearce DD, et al. Interest, concerns, and attitudes among men who have sex with men and Health Care providers toward prophylactic use of doxycycline against Chlamydia trachomatis infections and Syphilis. Sex Transm Dis. 2021;48:615–9. https://doi.org/10.1097/OLQ.0000000000001395 .
doi: 10.1097/OLQ.0000000000001395
pubmed: 33560092
pmcid: 8521638
Chow EPF, Fairley CK. Use of doxycycline prophylaxis among gay and bisexual men in Melbourne. Lancet HIV. 2019;6:e568. https://doi.org/10.1016/S2352-3018(19)30186-9 . 569.
doi: 10.1016/S2352-3018(19)30186-9
pubmed: 31498105
Evers Y, van Liere G, Dukers-Muijrers N, et al. Use of doxycycline and other antibiotics to prevent STIs among men who have sex with men visiting sexual health clinics in the Netherlands. Sex Transm Infect. 2020;96:550–1. https://doi.org/10.1136/sextrans-2019-054325 .
doi: 10.1136/sextrans-2019-054325
pubmed: 31879360
Ahaus P, Schmidt AJ, Skaletz-Rorowski A, et al. Changes in the user profiles of HIV pre-exposure prophylaxis (PrEP) before and after PrEP reimbursement. J Infect Public Health. 2022;15:955–60. https://doi.org/10.1016/j.jiph.2022.07.012 .
doi: 10.1016/j.jiph.2022.07.012
pubmed: 35926293
O’Halloran C, Croxford S, Mohammed H, et al. Factors associated with reporting antibiotic use as STI prophylaxis among HIV PrEP users: findings from a cross-sectional online community survey, May–July 2019, UK. Sex Transm Infect. 2021;97:429–33. https://doi.org/10.1136/sextrans-2020-054592 .
doi: 10.1136/sextrans-2020-054592
pubmed: 33082235
Wilson DP, Prestage GP, Gray RT, et al. Chemoprophylaxis is likely to be acceptable and could mitigate syphilis epidemics among populations of gay men. Sex Transm Dis. 2011;38:573–9. https://doi.org/10.1097/OLQ.0b013e31820e64fd .
doi: 10.1097/OLQ.0b013e31820e64fd
pubmed: 21343845
Ambrosioni J, Levi L, Alagaratnam J, et al. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 2023;24:1126–36. https://doi.org/10.1111/hiv.13542 .
doi: 10.1111/hiv.13542
pubmed: 37849432
Werner RN, Schmidt AJ, Potthoff A, et al. Position statement of the German STI Society on the prophylactic use of doxycycline to prevent STIs (Doxy-PEP, Doxy-PrEP). J Dtsch Dermatol Ges. 2023 https://doi.org/10.1111/ddg.15282 .
doi: 10.1111/ddg.15282
pubmed: 38161245
Molina J-M, Bercot B, Assoumou L, ANRS 174 DOXYVAC: AN OPEN-LABEL RANDOMIZED TRIAL TO PREVENT STIs IN MSM ON PrEP. 2023. https://www.croiconference.org/abstract/anrs-174-doxyvac-an-open-label-randomized-trial-to-prevent-stis-in-msm-on-prep/ . Accessed 24. Nov 2023.
La Ruche G, Goubard A, Bercot B, et al. Gonococcal infections and emergence of gonococcal decreased susceptibility to cephalosporins in France, 2001 to 2012. Euro Surveill. 2014;19. https://doi.org/10.2807/1560-7917.es2014.19.34.20885 .
Jansen K, Selb R, Tamminga T. Deutsche Gonokokken-Resistenz- Surveillance (Go-SURV). 2021. https://www.rki.de/DE/Content/InfAZ/G/Gonorrhoe/GORENET/GORENET-Bericht_2021.pdf?__blob=publicationFile . Accessed 29. Nov 2023.
Wi T, Lahra MM, Ndowa F, et al. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLOS Med. 2017;14:e1002344. https://doi.org/10.1371/journal.pmed.1002344 .
doi: 10.1371/journal.pmed.1002344
pubmed: 28686231
pmcid: 5501266
Abara WE, Bernstein KT, Lewis FMT, et al. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study. Lancet Infect Dis. 2022;22:1021–9. https://doi.org/10.1016/S1473-3099(21)00812-4 .
doi: 10.1016/S1473-3099(21)00812-4
pubmed: 35427490
pmcid: 10227473
European AIDS, Treatment Goup. ANRS Doxyvac: final analysis may modify interim results of this trial assessing the effectiveness of meningococcal B vaccination in preventing gonococcal infections. 2023. https://www.eatg.org/hiv-news/anrs-doxyvac-final-analysis-may-modify-interim-results-of-this-trial-assessing-the-effectiveness-of-meningococcal-b-vaccination-in-preventing-gonococcal-infections/ . Accessed 7. Dec 2023.